Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial

Royce, Melanie; BACHELOT, Thomas; VILLANUEVA, Cristian; Ozguroglu, Mustafa; AZEVEDO, Sergio; CRUZ, Felipe; DEBLED, Marc; Hegg, Roberto; TOYAMA, Tatsuya; FALKSON, Carla; JEONG, Joon; SRIMUNINNIMIT, Vichien; Gradishar, William; ARCE, Christina; RIDOLFI, Antonia; LIN, Chinjune; CARDOSO, Fatima

doi:10.1001/jamaoncol.2018.0060

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial

Royce M., BACHELOT T., VILLANUEVA C., Ozguroglu M., AZEVEDO S. J., CRUZ F. M., ...More

JAMA ONCOLOGY, vol.4, no.7, pp.977-984, 2018 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 4 Issue: 7
Publication Date: 2018
Doi Number: 10.1001/jamaoncol.2018.0060
Journal Name: JAMA ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.977-984
Istanbul University Affiliated: Yes

Abstract

IMPORTANCE Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer.